GSK, Prosensa muscular dystrophy drug misses study goal
LONDON, Sept 20 (Reuters) - An experimental drug for Duchenne muscular dystrophy from GlaxoSmithKline (Other OTC: GLAXF - news) and Prosensa failed to meet its goal in a late-stage clinical trial, the companies said on Friday.
The drug, drisapersen, did not show a statistically significant improvement in the distance that patients could walk in six minutes compared to placebo in the Phase III test.